One To Watch

Nanobiotix

A Paris-based nanomedicine company whose hafnium-oxide radioenhancer NBTXR3, now licensed to Johnson & Johnson as JNJ-1900, is redefining what radiotherapy can do in solid tumors.

Company Overview

A Paris-based nanomedicine company whose hafnium-oxide radioenhancer NBTXR3, now licensed to Johnson & Johnson as JNJ-1900, is redefining what radiotherapy can do in solid tumors. Nanobiotix's core thesis is that physical amplification of radiation energy inside tumor cells — rather than biological modulation — offers a mechanism-agnostic route to improved local tumor control across multiple cancer types. The company trades on both Euronext Paris (NANO) and Nasdaq (NBTX), giving it dual capital market access unusual for a European clinical-stage biotech. The oversubscribed €85 million global offering closed in May 2026 signals continued investor conviction in the platform's breadth.

Headquarters and Global Presence

Nanobiotix is headquartered in Paris, France, and has expanded into the US life sciences cluster with an office in Boston, Massachusetts — a move that tracks the strategic importance of the Janssen partnership and Nasdaq listing. Manufacturing and supply operations are run from a dedicated team established under the company's earlier commercial infrastructure.

Founding and History

Laurent Levy co-founded Nanobiotix in Paris in 2003, building from the ground up on the physics of nanoparticle-radiation interaction — an approach that sat well outside mainstream oncology at the time. The company secured CE marking for NBTXR3 (marketed as Hensify in Europe) in soft tissue sarcoma, its first regulatory approval, before the strategic pivot toward a major pharma partnership. The landmark global licensing deal with Janssen (Johnson & Johnson) signed in July 2023, worth up to $2.6 billion in milestones, validated two decades of platform development. A new subsidiary was also launched to advance the company's "nanoprimer" technology concept, signaling an ambition to extend beyond the lead asset.

Therapy Areas and Focus

Nanobiotix is focused exclusively on oncology, with NBTXR3 currently in active development for head and neck cancer and non-small cell lung cancer — two indications where radiotherapy is already standard of care and where intensification of the local radiation effect could meaningfully shift outcomes. The company has also begun exploring NBTXR3's immunostimulatory properties, reasoning that the cell death triggered by nanoparticle-enhanced radiation may prime systemic immune responses — a hypothesis that, if validated, would substantially expand addressable indications. Soft tissue sarcoma remains the anchor indication with existing CE marking in Europe.

Technology Platforms and Modalities

The NanoXray platform centers on NBTXR3, a suspension of hafnium-oxide nanoparticles injected intratumorally and activated by standard external beam radiotherapy. Hafnium has a high atomic number, causing nanoparticles to absorb significantly more ionizing energy than surrounding tissue and deposit it as localized electron showers that damage tumor DNA beyond what radiation alone achieves. The mechanism is physical rather than biological, which means it is not subject to the resistance pathways that blunt targeted therapies and immunotherapies. A separate "nanoprimer" approach, housed in the new subsidiary, is exploring whether nanoparticle pre-treatment can condition the tumor microenvironment to enhance immunotherapy response.

Key Pipeline and Programs

NBTXR3 / JNJ-1900 is the company's sole clinical-stage asset and its entire near-term commercial story. In head and neck cancer, it is being evaluated in combination with radiotherapy and anti-PD-1 checkpoint inhibition — an indication where the combination of local radioenhancement and immune priming is most scientifically coherent. In non-small cell lung cancer, the compound is under investigation as a radioenhancer for patients receiving definitive or consolidative radiotherapy, a setting where local control failure remains a major cause of mortality. Both programs are being driven by Janssen under the global licensing agreement, with Nanobiotix retaining royalty rights. In Europe, NBTXR3 already holds CE marking as Hensify for locally advanced soft tissue sarcoma — the approved indication that anchors its regulatory credibility and provided the clinical proof of concept that attracted J&J. The European regulatory classification of NBTXR3 was reinforced in July 2025 following a reclassification announcement that the company described as strengthening the asset's global positioning.

Recent Developments

In July 2025, Nanobiotix announced two regulatory developments reinforcing NBTXR3's European positioning, including a formal reclassification, sending shares up nearly 7%. In March 2025, the company amended its Janssen licensing agreement — described as a disciplined financial strategy step — triggering a 17.6% single-day share gain. Most recently, in May 2026, Nanobiotix priced an oversubscribed €85 million global offering at approximately $100 million gross proceeds after exercise of the over-allotment option, with Jefferies, TD Cowen, and Stifel acting as joint bookrunners. The oversubscription in a difficult capital environment for biotech is a meaningful signal of institutional appetite for the NBTXR3 story.

Key Personnel

Laurent Levy serves as co-founder, Chairman of the Executive Board, and Chief Executive Officer, having led the company from its 2003 founding through CE approval and the J&J partnership. Edwina Baskin-Bey serves as Chief Medical Officer, joining from Innocrin Pharmaceuticals where she held the same role. Alain Dostie serves as Chief Operating Officer, bringing commercial oncology experience from Novartis prior to joining Nanobiotix.

Strategic Partnerships

The defining partnership is the July 2023 global licensing agreement with Janssen Pharmaceutica (Johnson & Johnson), under which NBTXR3 was rebranded JNJ-1900 and Janssen assumed global development responsibility; Nanobiotix is eligible for up to $2.6 billion in milestones plus tiered double-digit royalties. That agreement was amended in March 2025 in terms the company characterized as financially disciplined, though full deal economics of the amendment were not separately disclosed. Earlier regional deals include a strategic Asia-Pacific partnership with Taiwan's PharmaEngine, which joined the pivotal soft tissue sarcoma trial and triggered a $1 million milestone payment.

FAQ Section

J&J's bet is that NBTXR3's physical mechanism — boosting radiation energy deposition inside tumor cells regardless of molecular subtype — gives it a breadth that biologics and small molecules cannot match. Radiotherapy is used in roughly half of all cancer patients, so a validated radioenhancer commands a vast addressable patient population across multiple tumor types and geographies. The combination of CE-marked approval in sarcoma, early signals in head and neck cancer and NSCLC, and the immunostimulatory hypothesis gave J&J a multi-indication platform story, not a single-drug bet.

Hafnium's high atomic number (Z=72) means its electrons absorb far more ionizing radiation per unit mass than soft tissue — the photoelectric effect scales sharply with atomic number — releasing secondary electrons that inflict dense, localized DNA damage. Earlier nanoparticle radioenhancer attempts used gold or other heavy metals, but hafnium oxide offers a favorable combination of stability, biocompatibility, and radiation absorption profile at clinical X-ray energies. Manufacturing reproducible nanoparticle suspensions at pharmaceutical grade is itself a significant technical barrier that Nanobiotix spent years addressing, and that manufacturing know-how is part of what makes the asset defensible.

Standard radioimmunotherapy combinations rely on checkpoint inhibitors doing biological work — releasing existing immune brake mechanisms — while the radiation provides tumor antigen release opportunistically. NBTXR3 amplifies the radiation-induced tumor cell kill first, generating a larger and more immunogenic cell death signal before the immune system is engaged; the nanoprimer concept takes this further by hypothesizing that pre-treatment can actively condition the tumor microenvironment. The physical mechanism also means it is not subject to PD-L1 expression status, tumor mutational burden, or the resistance mutations that limit checkpoint monotherapy — a differentiation that is commercially meaningful in checkpoint-refractory populations.

Both programs are being driven by Janssen under the global license. In head and neck cancer, NBTXR3 is under evaluation combined with radiotherapy and anti-PD-1 immunotherapy — a setting where local control and immune priming are both clinically urgent. In non-small cell lung cancer, the compound is being investigated as a radioenhancer in patients receiving definitive or consolidative radiotherapy, where locoregional failure remains a major unmet need. Nanobiotix has not separately disclosed Phase III enrollment milestones for these indications in the available record, with Janssen managing operational disclosure.

Head and neck cancer and non-small cell lung cancer are the two active expansion indications for JNJ-1900, both chosen because radiotherapy is already a backbone of standard care and NBTXR3 can be layered onto existing treatment without requiring a new treatment paradigm. The immuno-oncology hypothesis — that nanoparticle-enhanced radiation primes systemic immune responses — opens a longer-term path into indications where immunotherapy is the dominant modality but where local tumor debulking would improve systemic outcomes. The nanoprimer subsidiary signals a second-generation platform ambition beyond pure radioenhancement.

Nanobiotix is a late clinical-stage company with one approved product (Hensify, CE marked in soft tissue sarcoma in Europe) and two active expansion programs in oncology under Janssen's stewardship. The May 2026 €85 million oversubscribed equity raise provides runway to advance the nanoprimer subsidiary and maintain the research infrastructure that underpins the J&J partnership. The European reclassification of NBTXR3 in July 2025 was a meaningful regulatory step in securing the asset's commercial positioning across EU markets ahead of potential label expansions.

The investment case turns on a small number of high-stakes variables — all worth tracking closely:

Phase III data from Janssen-run trials in head and neck cancer and NSCLC: positive readouts would trigger substantial milestone payments and validate the multi-indication thesis.
Milestone payment triggers under the J&J agreement: each disclosed payment event serves as an external validation signal and cash event for Nanobiotix.
Clinical validation of the immunostimulatory hypothesis: if NBTXR3-enhanced radiation demonstrably primes systemic immune response, the addressable indication set expands materially.
Execution risk on Janssen's end: Nanobiotix has ceded development control; any Janssen strategic re-prioritization would directly affect timelines.
Dilution risk: the May 2026 equity raise, while oversubscribed, adds to a share count that has grown alongside the company's capital needs.

Want to Update your Company's Profile?